Gosset Ownership
Private
Employees
~10
Stage
Phase 2
Modalities
Glyscend Therapeutics General Information
Lead candidate GLY-200 demonstrated clinically meaningful reductions in fasting and postprandial glucose, fasting lipids, body weight, food intake, and appetite vs placebo in a completed two-week study in T2D patients. Currently in Phase 2 trials for obesity.
Drug Pipeline
GLY-200
Phase 2Key Partnerships
Glyscend Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|
To view Glyscend Therapeutics's complete valuation and funding history, request access »